ovarian adnexal mass
Aspira Q2 Revenues More Than Double
The company reported total revenues of $1.8 million, up from $746,000Â a year ago, and posted sales of 4,553 OVA1plus tests, up from 2,458 in Q2 2020.
The company is developing tests for ovarian mass monitoring and endometriosis that it hopes will expand its addressable market beyond that targeted by OVA1.
Aspira Q4 Revenues Up 11 Percent, Firm Inks Deal for Ovarian Cancer Detection Tech
The agreement is with the Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz.
InterVenn Biosciences to Develop Cancer Tests, Expand Services Business With New Funding
The glycoproteomics firm is using its mass spec platform for ovarian cancer and immunotherapy tests as well as service work for pharma and other partners.
Aspira Q3 Revenues Down 8 Percent
For the three months ended Sept. 30, the firm said that total revenues fell to $1.2 million from $1.3 in the year-ago quarter with OVA1 volumes essentially flat.
Aug 13, 2020
Aspira Q2 Revenues Down 32 Percent
Jul 1, 2020
Aspira Eyes $11M in Private Equity Financing
May 14, 2020
Vermillion Q1 Revenues Up 55 Percent
Mar 26, 2020
Vermillion Q4 Revenues Up 42 Percent
Nov 13, 2019
Nov 12, 2019
Vermillion Q3 Revenues Up 66 Percent
May 14, 2019
Vermillion Q1 Revenues Up 24 Percent
Mar 28, 2019
Vermillion Q4 Revenues Up 16 Percent
Jan 15, 2019
Cigna Covering Vermillion's OVA1 Ovarian Cancer Test
Dec 13, 2018
Nov 8, 2018
Vermillion Q3 2018 Revenues Up 12 Percent
Jul 27, 2018
Vermillion Receives Nasdaq Delisting Warning
May 14, 2018
Vermillion Q1 Revenues Down 11 Percent
Mar 13, 2018
Vermillion Q4 Revenues Down Just Under 1 Percent
Mar 7, 2018